Related Experiment Video

Updated: Aug 27, 2025

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.7K

STING Agonists in Head and Neck Squamous Cell Carcinoma

David G Wallington1, Joseph N Contessa, Thomas J Hayman

  • 1From the Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT.

Cancer Journal (Sudbury, Mass.)
|September 27, 2022
PubMed

Insights

Stimulator of interferon genes (STING) agonists show promise for head and neck squamous cell carcinoma (HNSCC). Combining STING activation with DNA-damaging agents, rather than monotherapy, may improve patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Head and neck squamous cell carcinoma (HNSCC) presents significant therapeutic resistance.
  • The Stimulator of interferon genes (STING) pathway is crucial for antitumor responses.
  • STING agonists are being developed as targeted therapies for HNSCC.

Purpose of the Study:

  • To review preclinical and clinical data on STING agonists in HNSCC.
  • To explore the potential of STING pathway activation in HNSCC treatment.
  • To identify strategies for enhancing STING agonist efficacy.

Main Methods:

  • Review of preclinical studies on STING agonists in HNSCC models.
  • Analysis of clinical trial data for STING agonists in HNSCC.
  • Evaluation of combination therapy approaches involving STING agonists.

Main Results:

  • STING agonists demonstrate preclinical efficacy as single agents and with PD-1 inhibitors.
  • Clinical efficacy of STING agonists as monotherapy in HNSCC has been limited.
  • Preclinical data suggest enhanced efficacy when STING agonists are combined with DNA-damaging agents.

Conclusions:

  • STING pathway activation is a promising therapeutic target for HNSCC.
  • Combination therapy with STING agonists and DNA-damaging agents warrants further investigation.
  • Optimizing STING agonist use may overcome therapeutic resistance in HNSCC.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
250
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
307
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
833
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
420